Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Safety, immunogenicity and effect on viral rebound of HTI vaccines in early treated HIV-1 infection: a randomized, placebo-controlled phase 1 trial.

Bailón L. et al, (2022), Nature medicine

Specific human cytomegalovirus signature detected in NK cell metabolic changes post vaccination.

Woods E. et al, (2021), NPJ vaccines, 6

Effect of epitope variant co-delivery on the depth of CD8 T cell responses induced by HIV-1 conserved mosaic vaccines

Wee EG. et al, (2021), Molecular Therapy - Methods & Clinical Development, 21, 741 - 753

Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial.

Fidler S. et al, (2020), Lancet (London, England), 395, 888 - 898

Novel Nested Peptide Epitopes Recognized by CD4+ T Cells Induced by HIV-1 Conserved-Region Vaccines.

Borthwick N. et al, (2020), Vaccines, 8

Corrigendum to 'Therapeutic vaccination refocuses T-cell responses towards conserved regions of HIV-1 in early treated individuals (BCN 01 study)' EClinicalMedicine 11 (2019) 65-80.

Mothe B. et al, (2020), EClinicalMedicine, 18

HIVconsv Vaccines and Romidepsin in Early-Treated HIV-1-Infected Individuals: Safety, Immunogenicity and Effect on the Viral Reservoir (Study BCN02).

Mothe B. et al, (2020), Frontiers in Immunology, 11

In vivo Effects of Romidepsin on T-Cell Activation, Apoptosis and Function in the BCN02 HIV-1 Kick&Kill Clinical Trial.

Rosás-Umbert M. et al, (2020), Frontiers in immunology, 11

Aiming for protective T-cell responses: a focus on the first generation conserved-region HIVconsv vaccines in preventive and therapeutic clinical trials

Hanke T., (2019), Expert Review of Vaccines, 1 - 13

Parallel Induction of CH505 B Cell Ontogeny-Guided Neutralizing Antibodies and tHIVconsvX Conserved Mosaic-Specific T Cells against HIV-1.

Wee EG. et al, (2019), Mol Ther Methods Clin Dev, 14, 148 - 160

Recombinant BCG Expressing HTI Prime and Recombinant ChAdOx1 Boost Is Safe and Elicits HIV-1-Specific T-Cell Responses in BALB/c Mice.

Kilpeläinen A. et al, (2019), Vaccines (Basel), 7

MTBVAC-Based TB-HIV Vaccine Is Safe, Elicits HIV-T Cell Responses, and Protects against Mycobacterium tuberculosis in Mice

Broset E. et al, (2019), Molecular Therapy - Methods and Clinical Development, 13, 253 - 264

Therapeutic Vaccination Refocuses T-cell Responses Towards Conserved Regions of HIV-1 in Early Treated Individuals (BCN 01 study).

Mothe B. et al, (2019), EClinicalMedicine, 11, 65 - 80

Efficient Induction of T Cells against Conserved HIV-1 Regions by Mosaic Vaccines Delivered as Self-Amplifying mRNA

Moyo N. et al, (2019), Molecular Therapy - Methods and Clinical Development, 12, 32 - 46

Effective Suppression of HIV-1 Replication by Cytotoxic T Lymphocytes Specific for Pol Epitopes in Conserved Mosaic Vaccine Immunogens.

Zou C. et al, (2019), J Virol

Identification of novel HIV-1-derived HLA-E-binding peptides.

Hannoun Z. et al, (2018), Immunol Lett

CD8+ T cells specific for conserved, cross-reactive Gag epitopes with strong ability to suppress HIV-1 replication.

Murakoshi H. et al, (2018), Retrovirology, 15

A Novel Vaccine Strategy Employing Serologically Different Chimpanzee Adenoviral Vectors for the Prevention of HIV-1 and HCV Coinfection.

Hartnell F. et al, (2018), Frontiers in immunology, 9

Randomized phase I trial HIV-CORE 003: Depletion of serum amyloid P component and immunogenicity of DNA vaccination against HIV-1.

Borthwick NJ. et al, (2018), PLoS One, 13

Randomized phase I trial HIV-CORE 003: Depletion of serum amyloid P component and immunogenicity of DNA vaccination against HIV-1.

Borthwick NJ. et al, (2018), PLoS One, 13

Load More

1
2
3
4
5
6
7
...
»

Include forthcoming?